Portfolio
3
companies
Constructive Bio
Constructive Bio rewrites genomes to turn living cells into sustainable biofactories.
Lightcast Discovery
Lightcast Discovery builds a novel single-cell functional analysis platform for life science research.
Syndex Bio
Syndex Bio advances next-generation molecular diagnostics with its proprietary methyl-copying PCR platform.
ARCH Venture Partners led the oversubscribed round alongside participation from +ND Capital, OMX Ventures, and Meltwind.
"Syndex Bio’s mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring."
The Series A round was led by Ahren, OMX Ventures, and Paladin Capital Group to develop biomanufacturing platforms.
"Synthetic genomics is redefining how we harness biology. Our suite of proprietary technologies and incomparable team allows us to build novel materials and products that will revolutionise drug manufacturing and discovery,"
M Ventures led the Series B round to support the company ahead of its commercial launch.
"The power of single-cell analysis to uncover the complexities of biology has become increasingly evident, but much of the work still focuses on the transcriptome as the primary readout."
